MX378707B - Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. - Google Patents
Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.Info
- Publication number
- MX378707B MX378707B MX2016014634A MX2016014634A MX378707B MX 378707 B MX378707 B MX 378707B MX 2016014634 A MX2016014634 A MX 2016014634A MX 2016014634 A MX2016014634 A MX 2016014634A MX 378707 B MX378707 B MX 378707B
- Authority
- MX
- Mexico
- Prior art keywords
- relates
- disorders
- treatment
- compounds
- inhibitor compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167490 | 2014-05-08 | ||
| EP14170616 | 2014-05-30 | ||
| PCT/EP2015/060166 WO2015169944A1 (en) | 2014-05-08 | 2015-05-08 | Compounds for treating ophthalmic diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016014634A MX2016014634A (es) | 2017-04-10 |
| MX378707B true MX378707B (es) | 2025-03-10 |
Family
ID=53051826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014634A MX378707B (es) | 2014-05-08 | 2015-05-08 | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11730716B2 (enExample) |
| EP (1) | EP3139914B1 (enExample) |
| JP (1) | JP6629840B2 (enExample) |
| KR (1) | KR102312186B1 (enExample) |
| CN (2) | CN116077665A (enExample) |
| AU (1) | AU2015257651B2 (enExample) |
| BR (1) | BR112016025997A8 (enExample) |
| CA (1) | CA2947067C (enExample) |
| CL (1) | CL2016002812A1 (enExample) |
| ES (1) | ES2960598T3 (enExample) |
| HK (1) | HK1231417A1 (enExample) |
| IL (1) | IL248732B (enExample) |
| MX (1) | MX378707B (enExample) |
| NZ (1) | NZ725574A (enExample) |
| PL (1) | PL3139914T3 (enExample) |
| SG (1) | SG11201608835VA (enExample) |
| WO (1) | WO2015169944A1 (enExample) |
| ZA (1) | ZA201607260B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| JP6629840B2 (ja) * | 2014-05-08 | 2020-01-15 | パノプテス・ファーマ・ゲーエムベーハー | 眼の疾患および障害を処置するための化合物 |
| ES2658310T3 (es) | 2014-12-23 | 2018-03-09 | 4D Pharma Research Limited | Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación |
| EP3193901B1 (en) | 2014-12-23 | 2018-04-04 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| TWI759266B (zh) | 2015-06-15 | 2022-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物之用途 |
| MA55434B1 (fr) | 2015-06-15 | 2022-02-28 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA45287A (fr) | 2015-11-20 | 2018-08-22 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| EP3397625A4 (en) * | 2015-12-30 | 2019-12-25 | Agios Pharmaceuticals, Inc. | TREATMENT OF TUMORS WITH MUTANT ISOCITRATE DEHYDROGENASE |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| PT3313423T (pt) | 2016-03-04 | 2019-07-10 | 4D Pharma Plc | Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| IL270066B2 (en) | 2017-04-24 | 2023-10-01 | Aurigene Oncology Ltd | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| RS61872B1 (sr) | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| RS63393B1 (sr) | 2017-06-14 | 2022-08-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| JP6840272B2 (ja) | 2017-06-14 | 2021-03-10 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| EP3638271B1 (en) | 2017-06-14 | 2020-10-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US20200121652A1 (en) * | 2017-06-16 | 2020-04-23 | The Doshisha | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
| EP3639854A4 (en) | 2017-06-16 | 2021-03-03 | The Doshisha | MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF |
| KR102861339B1 (ko) | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| BR112020017988A2 (pt) | 2018-03-09 | 2020-12-22 | Panoptes Pharma Ges.M.B.H. | Composição oftálmica |
| HUE067375T2 (hu) * | 2018-03-16 | 2024-10-28 | Immunic Ag | Új kalciumsó polimorfok gyulladásellenes, immunmodulátor és proliferáció elleni szerekként |
| AU2019242628A1 (en) | 2018-03-26 | 2020-09-24 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting dihydroorotate dehydrogenase |
| US12076315B2 (en) | 2020-03-20 | 2024-09-03 | Clear Creek Bio, Inc. | Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof |
| WO2021216548A1 (en) * | 2020-04-21 | 2021-10-28 | University Of Massachusetts | Methods and compositions for treatment of age-related macular degeneration |
| CN111638341A (zh) * | 2020-07-01 | 2020-09-08 | 山东凯歌智能机器有限公司 | 一种检测小细胞肺癌患者外周血循环肿瘤细胞pd-l1基因突变的试剂盒及检测方法 |
| US20230390276A1 (en) * | 2020-10-15 | 2023-12-07 | Aslan Pharmaceuticals Pte. Ltd. | Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor |
| US20240199535A1 (en) | 2021-04-09 | 2024-06-20 | Immunic Ag | Deuterated dhodh inhibitors |
| JP2025500176A (ja) | 2021-12-23 | 2025-01-09 | イミュニック アクチェンゲゼルシャフト | カルボン酸バイオアイソスタを含むｄｈｏｄｈ阻害剤 |
| CA3245254A1 (en) * | 2022-03-01 | 2023-09-07 | Kiora Pharmaceuticals Gmbh | SALTS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR |
| CA3245493A1 (en) | 2022-03-09 | 2023-09-14 | Kiora Pharmaceuticals Gmbh | POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR |
| TW202506107A (zh) | 2023-06-28 | 2025-02-16 | 德商埃慕尼克股份公司 | 雜芳族dhodh抑制劑 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61103836A (ja) | 1984-10-24 | 1986-05-22 | Green Cross Corp:The | フイブロネクチン製剤 |
| DD297328A5 (de) * | 1989-08-18 | 1992-01-09 | �������@���������k���Kk�� | 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen |
| CN1124158C (zh) | 1996-04-19 | 2003-10-15 | 株式会社·R-技术上野 | 含白蛋白为有效成分的药物组合物 |
| HUP9701554D0 (en) | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| WO2003006424A1 (en) | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| WO2004036182A2 (en) * | 2002-10-17 | 2004-04-29 | Control Delivery Systems, Inc. | Methods for monitoring treatment of disease |
| WO2004056747A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| US7071355B2 (en) * | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| BR0317687A (pt) * | 2002-12-23 | 2005-11-22 | 4Sc Ag | Compostos aromáticos como agentes antiinflamatórios, imunomoduladores e antiproliferativos |
| US7365094B2 (en) | 2002-12-23 | 2008-04-29 | 4Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| AU2005229356B2 (en) | 2004-03-11 | 2011-06-09 | Idorsia Pharmaceuticals Ltd | Tetrahydropyridoindole derivatives |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| JP2006089485A (ja) * | 2004-08-24 | 2006-04-06 | Santen Pharmaceut Co Ltd | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| WO2007038687A2 (en) * | 2005-09-27 | 2007-04-05 | Aciont, Inc. | Ocular administration of immunosuppressive agents |
| ES2319596B1 (es) * | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| JP2009270356A (ja) | 2008-05-08 | 2009-11-19 | Yoshinobu Hayashi | アスベスト含有被覆層剥ぎ取り物の処理方法 |
| TWI530286B (zh) | 2009-05-04 | 2016-04-21 | 帕納特斯製藥格斯有限公司 | 作為抑制病毒化合物之抗發炎劑 |
| US20110021465A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
| US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
| RS60051B1 (sr) * | 2011-06-10 | 2020-04-30 | Ramscor Inc | Formulacije sa produženim oslobađanjem za isporuku proteina u oko i postupci njihove pripreme |
| AU2014390300A1 (en) | 2014-04-11 | 2016-10-20 | Panoptes Pharma Gmbh | Anti-inflammatory agents as virostatic compounds |
| JP6629840B2 (ja) * | 2014-05-08 | 2020-01-15 | パノプテス・ファーマ・ゲーエムベーハー | 眼の疾患および障害を処置するための化合物 |
| EP3397625A4 (en) | 2015-12-30 | 2019-12-25 | Agios Pharmaceuticals, Inc. | TREATMENT OF TUMORS WITH MUTANT ISOCITRATE DEHYDROGENASE |
| BR112020017988A2 (pt) | 2018-03-09 | 2020-12-22 | Panoptes Pharma Ges.M.B.H. | Composição oftálmica |
| US20240199535A1 (en) | 2021-04-09 | 2024-06-20 | Immunic Ag | Deuterated dhodh inhibitors |
| CA3245254A1 (en) | 2022-03-01 | 2023-09-07 | Kiora Pharmaceuticals Gmbh | SALTS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR |
| CA3245493A1 (en) | 2022-03-09 | 2023-09-14 | Kiora Pharmaceuticals Gmbh | POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR |
-
2015
- 2015-05-08 JP JP2017510766A patent/JP6629840B2/ja not_active Expired - Fee Related
- 2015-05-08 CA CA2947067A patent/CA2947067C/en active Active
- 2015-05-08 BR BR112016025997A patent/BR112016025997A8/pt not_active Application Discontinuation
- 2015-05-08 EP EP15720340.7A patent/EP3139914B1/en active Active
- 2015-05-08 CN CN202310101659.5A patent/CN116077665A/zh active Pending
- 2015-05-08 CN CN201580036856.7A patent/CN106572968A/zh active Pending
- 2015-05-08 SG SG11201608835VA patent/SG11201608835VA/en unknown
- 2015-05-08 PL PL15720340.7T patent/PL3139914T3/pl unknown
- 2015-05-08 KR KR1020167033322A patent/KR102312186B1/ko active Active
- 2015-05-08 AU AU2015257651A patent/AU2015257651B2/en active Active
- 2015-05-08 US US15/309,176 patent/US11730716B2/en active Active
- 2015-05-08 WO PCT/EP2015/060166 patent/WO2015169944A1/en not_active Ceased
- 2015-05-08 ES ES15720340T patent/ES2960598T3/es active Active
- 2015-05-08 NZ NZ725574A patent/NZ725574A/en unknown
- 2015-05-08 MX MX2016014634A patent/MX378707B/es unknown
- 2015-05-08 HK HK17105296.1A patent/HK1231417A1/zh unknown
-
2016
- 2016-10-20 ZA ZA2016/07260A patent/ZA201607260B/en unknown
- 2016-11-03 IL IL248732A patent/IL248732B/en active IP Right Grant
- 2016-11-07 CL CL2016002812A patent/CL2016002812A1/es unknown
-
2023
- 2023-03-23 US US18/189,010 patent/US12364680B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11730716B2 (en) | 2023-08-22 |
| AU2015257651B2 (en) | 2020-01-23 |
| US20230285355A1 (en) | 2023-09-14 |
| CA2947067C (en) | 2023-02-14 |
| BR112016025997A8 (pt) | 2021-07-06 |
| US12364680B2 (en) | 2025-07-22 |
| AU2015257651A1 (en) | 2016-11-10 |
| IL248732B (en) | 2019-07-31 |
| EP3139914A1 (en) | 2017-03-15 |
| KR20160147023A (ko) | 2016-12-21 |
| WO2015169944A1 (en) | 2015-11-12 |
| PL3139914T3 (pl) | 2023-11-27 |
| CN116077665A (zh) | 2023-05-09 |
| IL248732A0 (en) | 2017-01-31 |
| MX2016014634A (es) | 2017-04-10 |
| NZ725574A (en) | 2022-08-26 |
| JP6629840B2 (ja) | 2020-01-15 |
| JP2017514917A (ja) | 2017-06-08 |
| EP3139914C0 (en) | 2023-07-26 |
| BR112016025997A2 (pt) | 2017-08-15 |
| EP3139914B1 (en) | 2023-07-26 |
| KR102312186B1 (ko) | 2021-10-14 |
| CN106572968A (zh) | 2017-04-19 |
| SG11201608835VA (en) | 2016-11-29 |
| ZA201607260B (en) | 2018-05-30 |
| ES2960598T3 (es) | 2024-03-05 |
| CL2016002812A1 (es) | 2017-03-17 |
| US20170071904A1 (en) | 2017-03-16 |
| HK1231417A1 (zh) | 2017-12-22 |
| CA2947067A1 (en) | 2015-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX378707B (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| TN2019000136A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| MX2018013472A (es) | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX393057B (es) | Compuestos de indol carboxamida útiles como inhibidores de cinasas. | |
| NZ708593A (en) | Novel pyrazole derivative | |
| EA201992607A1 (ru) | Твердые формы берберина урсодезоксихолата, их композиции и способы | |
| PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
| MX2015012653A (es) | Formulaciones oculares para suministro de farmaco al segmento porterior del ojo. | |
| MX385762B (es) | Métodos para el control transcripcional objetivo en regiones del super mejorador. | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| MX362485B (es) | Nuevos inhibidores de rock. | |
| MY201535A (en) | Therapeutic compounds | |
| EA202191684A1 (ru) | Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии | |
| WO2015048188A8 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| EA202191683A1 (ru) | Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| MX381932B (es) | Composicion intranasal que comprende betahistina. | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний | |
| BR112017021374A2 (pt) | ácido pirrolidona carboxílico (pca) para uso oftálmico | |
| CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| MX375329B (es) | 2,2,2-trifluoroetil-tiadiazinas. |